Long-term Blood Pressure Outcome After Unilateral Adrenalectomy for Primary Hyperaldosteronism (Hyperaldo)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03648294|
Recruitment Status : Completed
First Posted : August 27, 2018
Last Update Posted : August 27, 2018
To evaluate long-term results of adrenalectomy for primary aldosteronism (PA) and to identify prognostic factors associated.
Exhaustive retrospective review of all consecutive patients undergoing adrenalectomy for PA between 2002 and 2013 in our department. All patients underwent preoperative: clinical evaluation (age, sex, height, weight, systolic and diastolic BP under treatment, identification of anti-hypertension treatment), biological evaluation (potassium, renin, aldosterone) and radiological evaluation (CT and/or MRI). Blood pressure was assessed postoperatively at 1 month, 1 year, then at the date of the latest news. The patients were classified into three categories: cured (no antihypertensive therapy in postoperative associated with strictly lower blood pressures of 140/90mmHg), improved (decreased number of drugs or number unchanged but with better blood pressure control), and refractory (no change in the number of drug and blood pressure, or deterioration of one or other of these two parameters).
|Condition or disease||Intervention/treatment|
|Adrenalectomy; Status||Other: adrenalectomy for primary addosteronism|
|Study Type :||Observational|
|Actual Enrollment :||43 participants|
|Official Title:||Long-term Blood Pressure Outcome After Unilateral Adrenalectomy for Primary Hyperaldosteronism|
|Actual Study Start Date :||December 1, 2013|
|Actual Primary Completion Date :||January 31, 2017|
|Actual Study Completion Date :||January 31, 2017|
- Other: adrenalectomy for primary addosteronism
All of the clinical and biological data were retrospectively compiled from the patient computerized record. The variables analyzed were: age, sex, body mass index (BMI), PAH discovery circumstances, pre- and postoperative systolic and diastolic blood pressure assessments, number of pre-hypertensive antihypertensive drug - and postoperatively, the laterality, the size and nature of the lesions, the operating time, the surgical technique used. The biological data evaluated were pre- and postoperative plasma and plasma creatinine, preoperative serum aldosterone concentrations, plasma renin activity, and preoperative aldosterone / renin ratio. Hypokalemia was defined as serum concentration below 3.5 mmol / L.
- Adrenalectomy for primary hyperaldosteronism [ Time Frame: 1 year ]The objective of this study is to evaluate the course of the disease associated with long-term outcomes of adrenalectomy for the treatment of PAH, with a retrospective analysis of patient data!
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03648294
|Principal Investigator:||Fabien Saint, MD, PhD||CHU AMIENS|